Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 3/20 | 0.43 |
| ▸ | FABP3 | P05413 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28926577 | 0.76 | GABRA1 (0.45) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL3304566 | 0.76 | FABP4 (0.48) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL2588899 | 0.73 | GABRA1 (0.48) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL15345779 | 0.70 | CYP1A1 (0.33) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL9369688 | 0.69 | FABP4 (0.56) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL9064395 | 0.69 | GABRA1 (0.52) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL3079552 | 0.69 | GABRA1 (0.52) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL15329461 | 0.67 | APP (0.44) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL3843896 | 0.67 | GABRA1 (0.50) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL140258 | 0.67 | GABRA1 (0.50) | GABRA1GABRB2FABP4FABP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050329-A | Gold nanocluster and preparation method thereof | 闽江师范高等专科学校 | 2023-11-14 | — | — | CN | claimed |
| CN-117050329-A | Gold nanocluster and preparation method thereof | 闽江师范高等专科学校 | 2023-11-14 | — | — | CN | disclosed |
| CN-117050329-A | Gold nanocluster and preparation method thereof | 闽江师范高等专科学校 | 2023-11-14 | — | — | CN | disclosed |
| US-9403781-B2 | Crystalline 1H-1,2,3-triazol-5-ylidenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2011139704-A2 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | TCP1, CCT3, CCT2 | GABRA1 4399/4885GABRB2 4704/4885FABP4 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.